Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature

BACKGROUND: Oncocytic carcinoma of the thyroid is a rare disease, characterized by a poor prognosis and low response rate to radioiodine therapy. Crizotinib is a specific anaplastic lymphoma kinase (ALK) inhibitor, which was initially developed in non-small cell lung cancer. Other solid tumors harbo...

Descripción completa

Detalles Bibliográficos
Autores principales: de Salins, Victoire, Loganadane, Gokoulakrichenane, Joly, Charlotte, Abulizi, Mukedaisi, Nourieh, Maya, Boussion, Hélène, Belkacemi, Yazid, Tournigand, Christophe, Kempf, Emmanuelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407927/
https://www.ncbi.nlm.nih.gov/pubmed/32821654
http://dx.doi.org/10.5306/wjco.v11.i7.495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407927/
https://www.ncbi.nlm.nih.gov/pubmed/32821654
http://dx.doi.org/10.5306/wjco.v11.i7.495

Ejemplares similares